Micafungin
Active ingredient: Micafungin Sodium
In short: Micafungin for Injection is indicated for: Treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses in adult and pediatric patients 4 months of age and older . Treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses without meningo
What is Micafungin used for?
Micafungin for Injection is indicated for:
Treatment of Candidemia, Acute Disseminated Candidiasis,
Candida Peritonitis and Abscesses in adult and pediatric patients 4 months of age and older
.
Treatment of Candidemia, Acute Disseminated Candidiasis,
Candida Peritonitis and Abscesses
without
meningoencephalitis and/or ocular dissemination in pediatric patients younger than 4 months of age
.
Treatment of Esophageal Candidiasis in adult and pediatric patients 4 months of age and older
.
Prophylaxis of
Candida Infections in adult and pediatric patients 4 months of age and older undergoing hematopoietic stem cell transplantation
.
Limitations of Use
The safety and effectiveness of Micafungin for Injection have
not
been established for the treatment of candidemia
with
meningoencephalitis and/or ocular dissemination in pediatric patients younger than 4 months of age as a higher dose may be needed
.
Micafungin for Injection has not been adequately studied in patients with endocarditis, osteomyelitis and meningoencephalitis due to
Candida.
The efficacy of Micafungin for Injection against infections caused by fungi other than
Candida has not been established.
Micafungin dosage
The recommended dosage for adult patients based on indications are shown in Table 1.
Table 1. Micafungin for Injection Dosage in Adult Patients
​​Indication | Recommended Reconstituted Dose Once Daily
Treatment of Candidemia, Acute Disseminated Candidiasis,
Candida Peritonitis and Abscesses
* | 100 mg
Treatment of Esophageal Candidiasis
†| 150 mg
Prophylaxis of
Candida Infections in HSCT Recipients
‡ | 50 mg
*In patients treated successfully for candidemia and other
Candida infections, the mean duration of treatment was 15 days (range 10 to 47 days).
†In patients treated successfully for esophageal candidiasis, the mean duration of treatment was 15 days (range 10 to 30 days).
‡In hematopoietic stem cell transplant (HSCT) recipients who experienced success of prophylactic therapy, the mean duration of prophylaxis was 19 days (range 6 to 51 days).
The recommended dosage for pediatric patients 4 months of age and older based on indication and weight are shown in Table 2.
Table 2. Micafungin for Injection Dosage in Pediatric Patients (4 Months of Age and Older)
Indication | Dosage for Pediatric Patients 4 Months of Age and Older
30 kg or less | Greater than 30 kg
Treatment of Candidemia, Acute Disseminated Candidiasis,
Candida Peritonitis and Abscesses | 2 mg/kg once daily
(maximum daily dose 100 mg)
Treatment of Esophageal Candidiasis | 3 mg/kg once daily | 2.5 mg/kg once daily
(maximum daily dose 150 mg)
Prophylaxis of
Candida Infections in HSCT Recipients | 1 mg/kg once daily
(maximum daily dose 50 mg)
Treatment of Candidemia, Acute Disseminated Candidiasis,
Candida Peritonitis and Abscesses
without
meningoencephalitis and/or ocular dissemination
The recommended dosage is 4 mg/kg once daily.
The safety and effectiveness of micafungin for injection have
not
been established for the treatment of candidemia
with
meningoencephalitis and/or ocular dissemination in pediatric patients younger than 4 months of age as a higher dose may be needed
.
Do not mix or co-infuse micafungin for injection with other medications. Micafungin for injection has been shown to precipitate when mixed directly with a number of other commonly used medications. Please read this entire section carefully before beginning reconstitution.
Reconstitution
Reconstitute micafungin for injection vials by aseptically adding 5 mL of one of the following compatible solutions:
0.9% Sodium Chloride Injection, USP (without a bacteriostatic agent)
5% Dextrose Injection, USP
To minimize excessive foaming, gently dissolve the micafungin for injection powder by swirling the vial.
Do not vigorously shake the vial. Visually inspect the vial for particulate matter.
Micafungin for injection 50 mg vial: after reconstitution each mL contains 10 mg of micafungin. …
How to take Micafungin — instructions & advice from the label
Hypersensitivity
Inform patients about the serious adverse effects of micafungin for injection including hypersensitivity reactions e.g., anaphylaxis and anaphylactoid reactions including shock.
Hepatic
Inform patients about the serious adverse effects of micafungin for injection including hepatic effects e.g., abnormal liver tests, hepatic impairment, hepatitis or worsening hepatic failure.
Hematologic
Inform patients about the serious adverse effects of micafungin for injection including hematological effects e.g., acute intravascular hemolysis, hemolytic anemia and hemoglobinuria.
Renal
Inform patients about the serious adverse effects of micafungin for injection including renal effects e.g., elevations in BUN and creatinine, renal impairment or acute renal failure.
Embryo-Fetal Toxicity
Advise pregnant women and females of reproductive potential of the potential risk of micafungin for injection to a fetus. Advise females to inform their healthcare provider of a known or suspected pregnancy. …
Warnings & precautions
Do not take this medicine if: Micafungin for injection is contraindicated in persons with known hypersensitivity to micafungin, any component of micafungin for injection, or other echinocandins.
Isolated cases of serious hypersensitivity (anaphylaxis and anaphylactoid) reactions (including shock) have been reported in patients receiving micafungin for injection. If these reactions occur, micafungin for injection infusion should be discontinued and appropriate treatment administered.
Acute intravascular hemolysis and hemoglobinuria was seen in a healthy volunteer during infusion of micafungin for injection (200 mg) and oral prednisolone (20 mg). Cases of significant hemolysis and hemolytic anemia have also been reported in patients treated with micafungin for injection. Patients who develop clinical or laboratory evidence of hemolysis or hemolytic anemia during micafungin for injection therapy should be monitored closely for evidence of worsening of these conditions and evaluated for the risk/benefit of continuing micafungin for injection therapy.
Laboratory abnormalities in liver function tests have been seen in healthy volunteers and patients treated with micafungin for injection. In some patients with serious underlying conditions who were receiving micafungin for injection along with multiple concomitant medications, clinical hepatic abnormalities have occurred, and isolated cases of significant hepatic impairment, hepatitis, and hepatic failure have been reported. Patients who develop abnormal liver function tests during micafungin for injection therapy should be monitored for evidence of worsening hepatic function and evaluated for the risk/benefit of continuing micafungin for injection therapy. …
Micafungin side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
Hypersensitivity Reactions
Hematological Effects
Hepatic Effects
Renal Effects
Infusion and Injection Site Reactions
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of micafungin for injection cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in practice.
The overall safety of micafungin for injection was assessed in 520 healthy volunteers and 3417 adult and pediatric patients who received single or multiple doses of micafungin for injection across 50 clinical trials, including the invasive candidiasis, esophageal candidiasis and prophylaxis trials. The doses of micafungin for injection administered included doses above and below the recommended doses
and ranged from 0.75 mg/kg to 15 mg/kg in pediatric patients and 12.5 mg to 150 mg/day or greater in adults.
Clinical Trials Experience in Adults
In clinical trials with micafungin for injection, 2497/2748 (91%) adult patients experienced at least one adverse reaction. …
Drug interactions
CYP3A4, CYP2C9 and CYP2C19 Inhibitors
Co-administration of micafungin for injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin for injection.
CYP2C19 and CYP3A4 Inducer
Co-administration of micafungin for injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin for injection.
Co-administration of Micafungin for Injection with Other Drugs
Co-administration of micafungin for injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin for injection.
CYP3A4 Substrates
There was no effect of single or multiple doses of micafungin for injection on cyclosporine, tacrolimus, prednisolone, voriconazole and fluconazole pharmacokinetics.
Sirolimus AUC was increased by 21% with no effect on C
max in the presence of steady-state micafungin for injection compared with sirolimus alone. Nifedipine AUC and C
max were increased by 18% and 42%, respectively, in the presence of steady-state micafungin for injection compared with nifedipine alone. Itraconazole AUC and C
max were increased by 22% and 11%, respectively. …
About this medicine
Micafungin for Injection USP is a sterile, lyophilized product for intravenous (IV) infusion that contains Micafungin Sodium USP. Micafungin Sodium USP is a semisynthetic lipopeptide (echinocandin) synthesized by a chemical modification of a fermentation product of
Coleophoma empetri F-11899. Micafungin inhibits the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall.
Each single-dose vial contains 50 mg micafungin (equivalent to 50.86 mg Micafungin Sodium USP) or 100 mg micafungin (equivalent to 101.73 mg Micafungin Sodium USP), 200 mg lactose monohydrate, with citric acid and/or sodium hydroxide (used for pH adjustment). Micafungin for Injection USP must be diluted with 0.9% Sodium Chloride Injection, USP, or 5% Dextrose Injection, USP
. Following reconstitution with 0.9% Sodium Chloride Injection, USP, the resulting pH of the solution is between 5-7. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 230fcff4-ad4b-ea25-e063-6394a90a1fab. Read the full official label on DailyMed.
Related medicines
Amoxicillin Azithromycin Doxycycline Amoxicillin and Clavulanate Cephalexin Valacyclovir Sulfamethoxazole and Trimethoprim Nitrofurantoin